BusinessGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017By Nasdaq OMXNov 13, 2017, 2:01 PM UTC
BusinessGalectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXNov 7, 2017, 1:15 PM UTC
BusinessGalectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH CirrhosisBy Nasdaq OMXOct 20, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02By Nasdaq OMXSep 12, 2017, 12:30 PM UTC
BusinessClarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXAug 18, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXAug 14, 2017, 12:15 PM UTC
BusinessGalectin Therapeutics to Present at the Singular Research Summer ConferenceBy Nasdaq OMXJul 7, 2017, 4:00 PM UTC
BusinessGalectin Therapeutics Announces Important Milestones towards Completion of NASH CX TrialBy Nasdaq OMXJun 13, 2017, 12:30 PM UTC
